{"id":20126,"date":"2023-03-31T22:47:00","date_gmt":"2023-03-31T14:47:00","guid":{"rendered":"https:\/\/flcube.com\/?p=20126"},"modified":"2024-12-28T22:54:38","modified_gmt":"2024-12-28T14:54:38","slug":"scineuro-pharmaceuticals-and-secarna-pharmaceuticals-ink-cns-disease-research-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=20126","title":{"rendered":"SciNeuro Pharmaceuticals and Secarna Pharmaceuticals Ink CNS Disease Research Deal"},"content":{"rendered":"\n

China-based SciNeuro Pharmaceuticals and Germany\u2019s Secarna Pharmaceuticals GmbH & Co. KG have announced a research and option deal aimed at advancing treatments for central nervous system (CNS) diseases. According to the agreement, Secarna will utilize its nucleic acid discovery and development platform, LNAplus, to generate and profile antisense oligonucleotide (ASO) candidates against targets selected by SciNeuro. SciNeuro will subsequently have the option to secure worldwide exclusive development and commercialization rights. The financial details of the agreement have not been disclosed.<\/p>\n\n\n\n

Secarna’s LNAplus Platform and SciNeuro’s CNS Focus<\/strong>
Secarna Pharmaceuticals, a leading independent European company in next-generation antisense drug discovery and development, will apply its LNAplus platform to access targets often considered \u2018undruggable.\u2019 The company’s pipeline products address a range of diseases, including immuno-oncology, immunology, viral infections, neurodegenerative conditions, and cardiometabolic diseases. SciNeuro, on the other hand, specializes in R&D for neurodegenerative and CNS diseases, with facilities in Shanghai, China, and Maryland, US.<\/p>\n\n\n\n

Background on SciNeuro Pharmaceuticals<\/strong>
SciNeuro was established in 2020 by Dr. Min Li, who previously served as the head of GlaxoSmithKline’s research center in Shanghai until its closure in 2017. The company’s establishment marks a significant step in the advancement of CNS disease research and development, leveraging Dr. Li’s extensive experience in the pharmaceutical industry.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based SciNeuro Pharmaceuticals and Germany\u2019s Secarna Pharmaceuticals GmbH & Co. KG have announced a research…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[87,66,2989,2990],"class_list":["post-20126","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-chronic-disease","tag-gene-therapy","tag-scineuro-pharmaceuticals","tag-secarna-pharmaceuticals"],"yoast_head":"\nSciNeuro Pharmaceuticals and Secarna Pharmaceuticals Ink CNS Disease Research Deal - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based SciNeuro Pharmaceuticals and Germany\u2019s Secarna Pharmaceuticals GmbH & Co. KG have announced a research and option deal aimed at advancing treatments for central nervous system (CNS) diseases. According to the agreement, Secarna will utilize its nucleic acid discovery and development platform, LNAplus, to generate and profile antisense oligonucleotide (ASO) candidates against targets selected by SciNeuro. SciNeuro will subsequently have the option to secure worldwide exclusive development and commercialization rights. The financial details of the agreement have not been disclosed.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=20126\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SciNeuro Pharmaceuticals and Secarna Pharmaceuticals Ink CNS Disease Research Deal\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=20126\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-31T14:47:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-28T14:54:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20126#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20126\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"SciNeuro Pharmaceuticals and Secarna Pharmaceuticals Ink CNS Disease Research Deal\",\"datePublished\":\"2023-03-31T14:47:00+00:00\",\"dateModified\":\"2024-12-28T14:54:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20126\"},\"wordCount\":228,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Chronic disease\",\"Gene therapy\",\"SciNeuro Pharmaceuticals\",\"Secarna Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20126#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20126\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=20126\",\"name\":\"SciNeuro Pharmaceuticals and Secarna Pharmaceuticals Ink CNS Disease Research Deal - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-03-31T14:47:00+00:00\",\"dateModified\":\"2024-12-28T14:54:38+00:00\",\"description\":\"China-based SciNeuro Pharmaceuticals and Germany\u2019s Secarna Pharmaceuticals GmbH & Co. KG have announced a research and option deal aimed at advancing treatments for central nervous system (CNS) diseases. According to the agreement, Secarna will utilize its nucleic acid discovery and development platform, LNAplus, to generate and profile antisense oligonucleotide (ASO) candidates against targets selected by SciNeuro. SciNeuro will subsequently have the option to secure worldwide exclusive development and commercialization rights. The financial details of the agreement have not been disclosed.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20126#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20126\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20126#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SciNeuro Pharmaceuticals and Secarna Pharmaceuticals Ink CNS Disease Research Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"SciNeuro Pharmaceuticals and Secarna Pharmaceuticals Ink CNS Disease Research Deal - Insight, China's Pharmaceutical Industry","description":"China-based SciNeuro Pharmaceuticals and Germany\u2019s Secarna Pharmaceuticals GmbH & Co. KG have announced a research and option deal aimed at advancing treatments for central nervous system (CNS) diseases. According to the agreement, Secarna will utilize its nucleic acid discovery and development platform, LNAplus, to generate and profile antisense oligonucleotide (ASO) candidates against targets selected by SciNeuro. SciNeuro will subsequently have the option to secure worldwide exclusive development and commercialization rights. The financial details of the agreement have not been disclosed.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=20126","og_locale":"en_US","og_type":"article","og_title":"SciNeuro Pharmaceuticals and Secarna Pharmaceuticals Ink CNS Disease Research Deal","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=20126","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-03-31T14:47:00+00:00","article_modified_time":"2024-12-28T14:54:38+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=20126#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=20126"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"SciNeuro Pharmaceuticals and Secarna Pharmaceuticals Ink CNS Disease Research Deal","datePublished":"2023-03-31T14:47:00+00:00","dateModified":"2024-12-28T14:54:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=20126"},"wordCount":228,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Chronic disease","Gene therapy","SciNeuro Pharmaceuticals","Secarna Pharmaceuticals"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=20126#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=20126","url":"https:\/\/flcube.com\/?p=20126","name":"SciNeuro Pharmaceuticals and Secarna Pharmaceuticals Ink CNS Disease Research Deal - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-03-31T14:47:00+00:00","dateModified":"2024-12-28T14:54:38+00:00","description":"China-based SciNeuro Pharmaceuticals and Germany\u2019s Secarna Pharmaceuticals GmbH & Co. KG have announced a research and option deal aimed at advancing treatments for central nervous system (CNS) diseases. According to the agreement, Secarna will utilize its nucleic acid discovery and development platform, LNAplus, to generate and profile antisense oligonucleotide (ASO) candidates against targets selected by SciNeuro. SciNeuro will subsequently have the option to secure worldwide exclusive development and commercialization rights. The financial details of the agreement have not been disclosed.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=20126#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=20126"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=20126#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"SciNeuro Pharmaceuticals and Secarna Pharmaceuticals Ink CNS Disease Research Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20126","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20126"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20126\/revisions"}],"predecessor-version":[{"id":20129,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20126\/revisions\/20129"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20126"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20126"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20126"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}